businessman signing settlement document

After a busy 2025, this year is set to be a big one for major dangerous product lawsuits. Here are some of the top litigations to watch as 2026 gets underway.

Depo-Provera Lawsuits

The Depo-Provera lawsuits saw a big shakeup just last month after a major decision by the Food and Drug Administration.

These lawsuits center on claims that Pfizer failed to warn its customers of a possible connection between the popular birth control shot and a higher risk of developing meningioma brain tumors.

Now, the FDA has officially updated the Depo-Provera label to include a meningioma risk warning. This could cause serious issues for Pfizer’s early defense against these lawsuits.

The company has claimed that it cannot be blamed for failing to warn Depo users of a risk since the FDA had previously rejected a meningioma label update in 2024. But with the agency now formally approving a warning, it’s unclear if that argument can hold up.

There are currently more than 1,700 Depo-Provera lawsuits pending in federal court, with many others scattered across state courts.

Ozempic Lawsuits

Litigation involving Ozempic and other GLP-1 drugs has been ongoing for a couple of years over claims involving gastroparesis, a type of stomach paralysis.

But a new group of Ozempic lawsuits claiming that these drugs may cause vision loss is rapidly growing. Those cases claim that GLP-1 use could result in a higher risk of non-arteritic anterior ischemic optic neuropathy (NAION), also known as an eye stroke. It can cause rapid and permanent vision loss.

NAION lawsuits have now been consolidated into multidistrict litigation (MDL), which is a major step for these cases. They will be overseen by the same judge who is handling the gastroparesis cases, but will proceed entirely separately.

At the start of January, nearly 30 cases had been added to the MDL.

Talcum Powder Lawsuits

Johnson & Johnson has suffered a couple of critical defeats in recent weeks as lawsuits involving potential ties between its talc products and cancer continue to advance to trial.

In a major verdict given the thousands of similar pending talc lawsuits, a California jury ordered J&J to pay $40 million in an ovarian cancer bellwether trial.

The company had previously attempted to move past the more than 67,000 pending ovarian cancer lawsuits through a controversial settlement process known as the Texas Two-Step, which involves shuttering a subsidiary company. Johnson & Johnson opted to focus on taking these cases to trial after the bankruptcy strategy failed.

With more ovarian cancer trials coming, repeated losses could prompt J&J to rethink its strategy.

For years, J&J has also faced lawsuits claiming its talc could be connected to a higher risk of mesothelioma. In a stunning verdict last month, a Baltimore jury awarded a plaintiff more than $1.5 billion over these claims.